ArticleConsortium psychiatricum2025
Comparative Analysis of Corpus Callosum Lipidome and Transcriptome in Schizophrenia and Healthy Brain.
Article in Consortium psychiatricum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulation of oligodendrocyte metabolism and myelination by acetyl-L-carnitine in a mouse model of post-weaning social isolation.Translational psychiatry · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFunctional and structural studies of the brain highlight the importance of white matter alterations in schizophrenia. However, molecular studies of the alterations associated with the disease remain insufficient.
aimTo study the lipidome and transcriptome composition of the corpus callosum in schizophrenia, including analyzing a larger number of biochemical lipid compounds and their spatial distribution in brain sections, and corpus callosum transcriptome data. To integrate the results of molecular approaches to create a comprehensive molecular perspective of the disease.
methodsA total of 8 brain tissue samples (4 from healthy controls (HC) + 4 from schizophrenia patients (SZ)) were analyzed using high-performance liquid chromatography with mass spectrometry (HPLC-MS) and RNA sequencing for transcriptome profiling. Additionally, 6 brain tissue samples (3 HC + 3 SZ) were analyzed using matrix-assisted laser desorption/ionization mass spectrometric imaging (MALDI-MSI). This approach enabled the characterization of mRNA and lipids in brain tissue samples, and the spatial distribution of selected lipids within brain sections.
resultsThe analysis revealed a general trend of reduced lipid levels in the corpus callosum of schizophrenia patients for lipid classes measured by mass spectrometric methods. Specifically, nine lipid classes detected via HPLC-MS showed significant differences in schizophrenia samples, with seven of them having lower median intensity. The results between HPLC-MS and MALDI-MSI were highly concordant. Transcriptome analysis identified 1,202 differentially expressed genes, clustered into four functional modules, one of which was associated with lipid metabolism.
conclusionWe identified a series of lipidome and transcriptome alterations in the corpus callosum of schizophrenia patients that were internally consistent and aligned well with previous findings on white matter lipidome changes in schizophrenia. These results add to the existing scope of molecular alterations associated with schizophrenia, shedding light on the biological processes potentially involved in its pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.